secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2025-10-09T23:59:59+00:00
Accession:  0001193125-25-235212
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha reports 100% milestone response in Phase 1/2 REVEAL Part A for TSHA-102; 165 additional functional gains
--------------------------------------------------------------------------------

- All 10 patients (Part A) achieved ≥1 natural-history-defined developmental milestone post-TSHA-102, 0% to <6.7% likelihood without treatment.
- 22 developmental milestones gained across domains of communication, fine motor, gross motor.
- Supplemental analysis: 165 additional skills/improvements across all 10 patients from structured scales (MSEL-A, R-MBA, ORCA).
- Data presented at 54th CNS Annual Meeting; reinforces broad, multi-domain impact on activities of daily living.
- Study evaluates high dose (1x10^15 vg) and low dose (5.7x10^14 vg) in females aged 6-21 years with Rett syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525235212/0001193125-25-235212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525235212/d949053d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-235212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer